Ibrutinib
Janssen,Abbvie
['cll']
i always love to see #asco22 abstracts coming from source-limited countries. this from lebanon describing epidemiological characteristics of lebanese patients with #cll patients in lebanon fcr and br are commonly used but also ibrutinib more recently 
Director-Heme Early Therapeutics & Leader-Leukemia/Myeloid Research @Yale. Personal views. I tweet on cancer, travel, food & soccer. COI: https://t.co/6XkF8CmtrK